{"id":1252,"date":"2026-09-01T16:54:32","date_gmt":"2026-09-01T16:54:32","guid":{"rendered":"https:\/\/vistaralabs.ca\/5-amino-1mq-research\/"},"modified":"2026-09-02T03:24:48","modified_gmt":"2026-09-02T03:24:48","slug":"5-amino-1mq-research","status":"publish","type":"post","link":"https:\/\/vistaralabs.ca\/fr\/5-amino-1mq-research\/","title":{"rendered":"5-Amino-1MQ : ce que couvre r\u00e9ellement la recherche sur la NNMT"},"content":{"rendered":"

5-Amino-1MQ<\/a> is not a peptide.<\/strong> It sits in peptide catalogues, gets ordered alongside peptides and is discussed in the same forums, but it is a small synthetic molecule \u2014 and the reason it is interesting has nothing to do with peptide signalling. It works on an enzyme most people have never heard of, and almost everything written about it traces back to the animal literature.<\/p>\n

That is not a reason to dismiss it. It is a reason to be precise about what the research actually covers, because the gap between the published work and the way this compound is described online is unusually wide.<\/p>\n

What 5-Amino-1MQ actually is<\/h2>\n

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase<\/strong>, usually shortened to NNMT. It is membrane-permeable, which matters \u2014 it can get inside a cell to reach the enzyme, rather than acting on a receptor at the cell surface the way most compounds in a peptide catalogue do.<\/p>\n

This is the first thing that gets lost. Retatrutide<\/a> and tirzepatide<\/a> are receptor agonists: they bind incretin receptors and trigger a signalling cascade. 5-Amino-1MQ does the opposite kind of job \u2014 it blocks an enzyme from doing its work inside the cell. Grouping them together because they all appear under “metabolic research” obscures that they are not remotely the same class of intervention.<\/p>\n

Why it is red<\/h2>\n

Open a box of research compounds and most of the vials look the same: white powder, or clear glass. 5-Amino-1MQ does not. It carries an orange-red colour that people notice immediately and often misread as a warning sign.<\/p>\n

It is not. The colour is a property of the molecule itself.<\/p>\n

A quinolinium ring is a fully conjugated aromatic system carrying a positive charge \u2014 electron-poor, in other words. The amino group sitting on that ring is the opposite: a strong electron donor. Put a donor and an acceptor at opposite ends of a conjugated system and you narrow the energy gap between the molecule’s electronic states. Narrow it far enough and the absorption band moves out of the ultraviolet and into visible light. The molecule starts absorbing part of the visible spectrum, and you see whatever is left over.<\/p>\n

That is the same principle that makes synthetic dyes coloured, and it is why an amino-substituted quinolinium compound is coloured while an unsubstituted one is far less so. The colour is structural. A batch of this compound being colourless would be more surprising than a batch being red.<\/p>\n

It is worth contrasting with GHK-Cu, which is blue<\/a>, because the two colours come from completely different physics. GHK-Cu<\/a>‘s blue comes from the copper ion \u2014 light absorbed by electronic transitions within the metal’s d-orbitals, which exist only because the copper is held in a particular geometry by the peptide. Remove the copper and the blue goes with it. 5-Amino-1MQ has no metal in it at all; its colour comes from the organic framework itself.<\/p>\n

One practical caveat, and it cuts against the intuition people usually bring to this. Compounds in this class are supplied as salts, and the counter-ion is the part most likely to differ between suppliers. Shade can therefore vary somewhat without the active molecule differing at all. Colour is not a purity test.<\/strong> It tells you the conjugated system is intact; it tells you nothing about what else is in the vial, which is what a certificate of analysis is for.<\/p>\n

What NNMT does, and why anyone would inhibit it<\/h2>\n

NNMT takes nicotinamide \u2014 a form of vitamin B3 \u2014 and attaches a methyl group to it, producing 1-methylnicotinamide. To do that it consumes S-adenosylmethionine, the cell’s main methyl donor.<\/p>\n

So the enzyme sits at a junction of two things researchers care about. It uses up nicotinamide, which is also a substrate the cell can recycle into NAD+<\/a>, and it uses up methyl groups. In tissues where NNMT is highly expressed \u2014 fat tissue and liver among them \u2014 the proposal is that a lot of enzymatic activity is running through this junction, and that inhibiting it shifts the balance.<\/p>\n

That is the hypothesis the field is built on. It is a mechanistically clean idea, which is part of why it has attracted attention, and it is worth separating a clean hypothesis from a demonstrated outcome.<\/p>\n

Where the fat-metabolism research points<\/h2>\n

The foundational work is genetic rather than pharmacological. In 2014, researchers publishing in Nature<\/em> knocked down NNMT in the fat tissue and liver of mice and reported that the animals were protected against diet-induced obesity \u2014 they gained less fat on a high-fat diet than controls did, without a reduction in how much they ate.<\/p>\n

That last detail is the one that made the field interesting. A compound that reduces fat mass by suppressing appetite is doing something well understood. An intervention that changes fat mass while food intake stays flat is pointing at energy handling inside the cell, which is a different and less crowded question.<\/p>\n

The small-molecule work followed. A 2018 paper in Biochemical Pharmacology<\/em> described selective, membrane-permeable NNMT inhibitors \u2014 5-Amino-1MQ among them \u2014 and reported reduced fat mass in diet-induced obese mice. This is the study almost every online description of 5-Amino-1MQ is ultimately quoting, usually without saying so.<\/p>\n

Work has continued. A 2024 paper in Diabetes, Obesity and Metabolism<\/em> reported that NNMT inhibition mitigated obesity-related metabolic dysfunction, and separate work has examined how NNMT behaves during beige fat development. Review articles through 2024\u20132026 have started treating NNMT as a translational target rather than a curiosity.<\/p>\n

\n

Every result described above is from animal or cell research.<\/strong> References are listed at the end of this article so the underlying papers can be read directly.<\/p>\n<\/div>\n

The honest state of the evidence<\/h2>\n

A search of the published clinical literature returns no completed human clinical trials of an NNMT inhibitor<\/strong>. Not small ones, not equivocal ones \u2014 none. The 2026 review in Trends in Pharmacological Sciences<\/em> is titled around emerging opportunities for clinical translation<\/em>, which is an accurate description of where things stand: translation is the thing being argued for, not the thing that has happened.<\/p>\n

Three limitations are worth stating plainly:<\/p>\n